← All trials
NCT03027557
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2017
- Primary completion
- Mar 1, 2019
- Completion date
- Mar 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Aalborg UniversityLead sponsor
- Aalborg UniversitySponsor investigator
- Aalborg UniversityCollaborator
- Aalborg UniversityOverall official - principal investigator
- Aalborg UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.